Cefuroxime: Clinical Use, Mechanisms, and Administration Guide

Cefuroxime is a second-generation cephalosporin antibiotic used to treat a broad range of bacterial infections, from pneumonia and sinusitis to urinary tract infections, skin infections, and early Lyme disease. It works by binding to proteins that bacteria need to build their cell walls, ultimately killing them. What makes cefuroxime distinctive among older cephalosporins is a structural tweak that gives it unusual resistance to the enzymes many bacteria produce to destroy antibiotics, and the fact that it comes in both an injectable form and an oral prodrug, allowing doctors to start treatment intravenously and then switch patients to pills without changing the active drug.

How Cefuroxime Kills Bacteria

Like all beta-lactam antibiotics, cefuroxime targets penicillin-binding proteins (PBPs), enzymes that bacteria rely on to cross-link the building blocks of their cell walls. When cefuroxime binds tightly enough to these proteins, the bacterium can no longer assemble or maintain its wall and dies. The strength of that binding matters: molecular modeling of how cefuroxime interacts with PBPs in different bacterial strains shows that when the drug binds tightly, the bacterium is killed, but when the binding is weak, the bacterium can keep functioning and survive.¹

Cefuroxime was the first beta-lactam antibiotic engineered with a methoxy-imino side chain at a key position on its cephalosporin ring, making it far more stable against beta-lactamase enzymes than earlier cephalosporins.² Beta-lactamases are the main weapon gram-negative bacteria use to chew up and inactivate cephalosporins, so this chemical feature widened the range of bacteria cefuroxime could handle compared with its predecessors.

Which Bacteria It Covers

Cefuroxime sits in a useful middle ground. It retains good activity against many gram-positive organisms, including staphylococci, pneumococci, and most streptococci, while extending its reach into gram-negative territory more than first-generation cephalosporins could. Early comparative studies found it more active than cefamandole against gonococci, pneumococci, and most streptococci, and roughly equivalent against Staphylococcus aureus and many members of the Enterobacteriaceae family.³

Haemophilus influenzae, a common cause of ear infections, sinusitis, and some pneumonias, is particularly susceptible to cefuroxime. Even ampicillin-resistant strains of H. influenzae showed no meaningful jump in resistance to cefuroxime, likely because the drug resists the beta-lactamases those strains produce.⁴ That stability is a big part of why cefuroxime became a workhorse for respiratory and ear infections.

There are clear gaps, though. Cefuroxime has limited activity against anaerobes like Bacteroides fragilis and does not cover Pseudomonas aeruginosa or many of the more resistant gram-negative hospital pathogens. It is not the right choice when those organisms are suspected.

Approved Clinical Uses

The oral form of cefuroxime, marketed as cefuroxime axetil, carries approvals for a wide list of common infections:

Respiratory infections: community-acquired pneumonia, acute and chronic bronchitis, sinusitis, pharyngitis, and tonsillitis.
Ear infections: otitis media, a particularly common indication in children.
Urinary tract infections: cystitis, urethritis, and pyelonephritis.
Gonorrhea: acute uncomplicated gonococcal urethritis and cervicitis.
Skin and soft tissue infections: furunculosis, pyoderma, and impetigo.
Early Lyme disease: an important alternative for patients who cannot take doxycycline.

These indications reflect the drug’s spectrum: it handles the organisms most commonly responsible for community-acquired infections while remaining well tolerated enough for outpatient use.⁵

Evidence in Pneumonia and Lyme Disease

For community-acquired pneumonia, oral cefuroxime axetil given twice daily performed as well as amoxicillin-clavulanate given three times daily, with a clinical cure or improvement rate of 100% among evaluable patients in one head-to-head trial, compared with 96% for amoxicillin-clavulanate.⁶ A larger multicenter trial comparing intravenous-to-oral cefuroxime against levofloxacin showed a clinical success rate of about 90% for the cefuroxime-based regimen, though levofloxacin edged it out at 96%.⁷ Both drugs achieved complete eradication of Streptococcus pneumoniae in blood cultures.

For early Lyme disease with erythema migrans (the characteristic “bull’s-eye” rash), two randomized trials found cefuroxime axetil and doxycycline essentially equivalent. In one trial, about 93% of patients on cefuroxime axetil had a satisfactory outcome versus 88% on doxycycline.⁸ A second trial found 90% versus 95%, with the confidence interval straddling zero in both studies, meaning neither drug was clearly superior.⁹ Cefuroxime axetil also appeared equally effective at preventing the progression to late Lyme disease. This makes it a valuable option for pregnant women or children under eight, for whom doxycycline is typically avoided.

The Oral Prodrug and Why Food Matters

Cefuroxime itself is poorly absorbed from the gut, so the oral version is actually cefuroxime axetil, an ester prodrug. After you swallow the tablet, enzymes in your intestinal lining and liver strip off the ester group, releasing active cefuroxime into the bloodstream. This conversion is not perfectly efficient: fasting absorption is only around 36% of the dose, but taking the tablet with food boosts that to roughly 52%, and peak blood levels climb by over 40%.¹⁰ This is not a minor difference. Taking cefuroxime axetil on an empty stomach could mean your blood levels are too low to clear the infection effectively. The standard advice is straightforward: take it with food or shortly after eating.

Where the Drug Goes in the Body

Cefuroxime distributes well into many tissues, but its penetration into the central nervous system is limited, which matters for brain or spinal infections. In neurointensive care patients receiving intravenous cefuroxime, brain tissue concentrations reached about a third of free plasma levels.¹¹ An animal model looking at spinal tissue found similar numbers: about 32% penetration into the spinal cord itself and only 7% into cerebrospinal fluid.¹²

In pediatric patients with infected cerebrospinal fluid shunts, intravenous cefuroxime at high doses did produce measurable levels in the ventricular fluid, but the concentrations varied widely from patient to patient.¹³ The practical takeaway is that cefuroxime is not a first-line drug for meningitis or deep central nervous system infections, where higher and more predictable brain penetration is critical.

Surgical Prophylaxis

Cefuroxime has a well-established role in preventing infections during and after surgery. Two areas stand out: cataract surgery and cardiac surgery.

In cataract surgery, injecting a small dose of cefuroxime directly into the eye at the end of the procedure has become standard practice in many countries. A large study from a high-volume center found that surgeries performed with intracameral cefuroxime prophylaxis had about 80% lower odds of postoperative endophthalmitis (a devastating eye infection) compared with surgeries without it, and when only culture-confirmed cases were counted, the reduction was about 92%.¹⁴ A separate study of over a million cataract procedures confirmed a significant reduction in endophthalmitis with cefuroxime injection, including among patients who experienced a capsular rupture during surgery, a complication that greatly raises infection risk.¹⁵

In cardiac surgery, cefuroxime is a recommended prophylactic antibiotic for surgical site infections, though researchers have flagged that the commonly used dosing schedules sometimes fail to keep blood levels high enough throughout long operations, especially when a heart-lung bypass machine dilutes the drug.¹⁶ This has prompted pharmacokinetic modeling efforts to optimize redosing intervals during prolonged procedures.

Kidney Function and Dose Adjustments

Cefuroxime is eliminated almost entirely through the kidneys in people with normal renal function, using both filtration and active secretion.¹⁷ As kidney function declines, the drug hangs around in the blood much longer. In patients with normal kidneys, the half-life of oral cefuroxime axetil is about an hour and a half. With moderate kidney impairment, it roughly doubles. With severe impairment, it can stretch to nearly 17 hours.¹⁸

The practical upshot: no dose adjustment is needed when creatinine clearance is above 50 mL/min. Below that threshold, the dosing interval needs to be stretched to prevent drug accumulation. For patients on hemodialysis, the drug is efficiently cleared during sessions, so an extra dose after dialysis is typically given.¹⁷

IV-to-Oral Stepdown Therapy

One of the practical advantages of cefuroxime is that the same active drug exists in both injectable and oral forms, making it a natural candidate for stepdown therapy. A patient admitted to the hospital with pneumonia might start on intravenous cefuroxime and switch to oral cefuroxime axetil tablets once they are improving, without changing the antibiotic. A study comparing twice-daily and three-times-daily IV cefuroxime followed by oral cefuroxime axetil found equivalent clinical response rates, with cure or improvement in roughly 80-84% of evaluable patients at the end of treatment.¹⁹

The cost benefit is real. An evaluation of IV-to-oral stepdown programs found that mean daily drug costs were significantly lower in the stepdown group compared with patients who stayed on IV therapy throughout their hospitalization.²⁰ Beyond drug costs, switching to oral therapy often allows patients to be discharged sooner, which brings further savings and gets people home faster.

Dosing and How Long the Drug Needs to Stay Active

Cefuroxime, like other beta-lactams, kills bacteria based on how long its concentration stays above the minimum inhibitory concentration (MIC) of the pathogen, not based on how high the peak level gets. The standard pharmacodynamic target is keeping the level above the MIC for at least 40-50% of the dosing interval.²¹ Simulation studies show that for Streptococcus pneumoniae (a major pneumonia pathogen), a modest IV dose every twelve hours hits this target easily. For Staphylococcus aureus, higher doses given every eight hours are needed. For tougher gram-negative pathogens like E. coli and Klebsiella, even high-dose regimens may not reach the target consistently, which helps explain why cefuroxime is not the preferred drug for complicated gram-negative infections.²²

For the oral tablets, modeling confirms that the standard 250 mg and 500 mg twice-daily doses meet the pharmacodynamic target for pathogens with lower MICs, covering most of the organisms cefuroxime is intended to treat under European susceptibility breakpoints.²³

Resistance Concerns

The same beta-lactamase stability that made cefuroxime a step forward over earlier cephalosporins has its limits. Extended-spectrum beta-lactamases (ESBLs) can break down not only cefuroxime but also third-generation cephalosporins like ceftriaxone.²⁴ ESBL-producing strains of Klebsiella pneumoniae have been documented to show high-level cefuroxime resistance, sometimes accompanied by shifts in their outer membrane proteins and a tenfold increase in resistance to unrelated antibiotic classes like fluoroquinolones.²⁵

In pneumococci with reduced penicillin susceptibility, the drug’s binding affinity for key PBPs drops as well, which can translate into clinical failures.²⁶ The practical implication is that cefuroxime works best in community settings where resistance rates are monitored and remain low. In hospitals with high rates of ESBL-producing organisms, broader-spectrum agents are usually needed.

Penicillin Allergy and Cross-Reactivity

Many patients who have been told they are allergic to penicillin worry about taking any cephalosporin. The risk is real but smaller than commonly believed, and it depends heavily on chemical structure. Cross-reactivity between penicillins and cephalosporins is driven primarily by their side chains, not by the core beta-lactam ring. When the side chain of the cephalosporin is different from the penicillin that caused the reaction, the risk of cross-reactivity is very low. A study that directly challenged 41 confirmed penicillin-allergic patients with cefuroxime (along with two other cephalosporins whose side chains differed from the offending penicillin) found that all 41 tolerated full therapeutic doses without any reaction.²⁷

The flip side: when a cephalosporin shares an identical side chain with the penicillin responsible for the allergy, cross-reactivity rates can exceed 30%.²⁸ Cefuroxime does not share its R1 side chain with amoxicillin or ampicillin, the two most common culprits in penicillin allergy. This does not mean it is risk-free for every penicillin-allergic person, but it does mean the blanket advice to avoid all cephalosporins if you are allergic to penicillin is outdated. If you have a documented penicillin allergy, your doctor can compare the side-chain structures and often find a cephalosporin, including cefuroxime, that is safe for you.

Use in Pregnancy and Children

Cefuroxime crosses the placenta. A study giving pregnant women a single IV dose before delivery found that fetal blood levels were dose-dependent, with the higher dose producing fetal concentrations likely to be effective for surgical prophylaxis.²⁹ This makes it useful as a prophylactic antibiotic during cesarean sections, and it is widely used in that role. Cefuroxime is classified as generally safe in pregnancy, though as with any medication, the decision involves weighing the infection risk against the drug exposure.

In children, there is one famously practical problem: taste. Cefuroxime axetil suspension is notoriously bitter. In a taste study comparing several antibiotic suspensions, children rated cefuroxime axetil’s flavor well below amoxicillin and similar to other poor-tasting alternatives. However, following the cefuroxime dose with a chocolate syrup chaser significantly improved aftertaste scores, with about 73% of children choosing the chocolate-chaser version as better tasting.²⁸ Pharmaceutical researchers have worked on polymer-based taste-masking formulations that hide the bitterness while still allowing the drug to dissolve properly in the stomach.³⁰ For parents dealing with a reluctant child, mixing the suspension with food or using a flavored chaser can make a real difference in whether the full course gets finished.

Common Side Effects

Cefuroxime is generally well tolerated. The most common side effects are gastrointestinal: nausea, diarrhea, and occasionally vomiting. These are typical of cephalosporins as a class and usually mild enough that most patients finish their course. As with all antibiotics, there is a risk of Clostridioides difficile-associated diarrhea, though second-generation cephalosporins are considered moderate risk in that regard compared with some broader-spectrum agents. Allergic reactions, including rash and, rarely, anaphylaxis, can occur, with the cross-reactivity considerations discussed above being relevant for patients with known beta-lactam allergies. Headache, dizziness, and transient increases in liver enzymes are occasionally reported but rarely require stopping the drug.

One side effect specific to the oral prodrug form deserves mention: because cefuroxime axetil tastes so unpleasant if the tablet is crushed, patients should swallow tablets whole. Crushing them not only ruins the taste but can also alter how quickly the drug is absorbed. If you cannot swallow tablets, the liquid suspension is the alternative, though with the flavor caveats noted above for children.³¹